| For: | Si Y, Tian B, Zhang R, Xuan MD, Liu KY, Jiao J, Han SS, Li HF, Hu YH, Zhao HY, He WJ, Wang J, Liu T, Yu WF. IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression. World J Gastroenterol 2025; 31(46): 111631 [PMID: 41479643 DOI: 10.3748/wjg.v31.i46.111631] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i46/111631.htm |
| Number | Citing Articles |
| 1 |
Sheng Xu, Zheng Zhu, Pei-Hong Shi, Yue-Ting Xu, Hui-Ming Zhang, Yang Zheng, Yi-Tong Chen, Guang-Rong Lu, Bin-Jiao Zheng. Letter to the Editor: Targeting the <i>IGF2BP3</i>/<i>FBXO32</i>/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy. World Journal of Gastroenterology 2026; 32(21): 116467 doi: 10.3748/wjg.v32.i21.116467
|
| 2 |
Binglun Zhang, Xue Ren, Bo Wang, Yuting Wang, Delong Zhang, Fanhe Meng. IGF2BP3 promotes glycolysis of osteosarcoma stem cells by reading RNA m⁶A to stabilize ENO1 and promote malignant biological behavior of osteosarcoma. Cell Biology and Toxicology 2026; 42(1) doi: 10.1007/s10565-026-10218-8
|
| 3 |
Qi-Yuan Feng, Si-Bi Yin, Ling-Yun Luo, Li-Yang Dai, Xue-Lian Luo. <i>IGF2BP3</i> in gastric cancer: Unraveling an N<sup>6</sup>-methyladenosine-driven oncogenic axis for therapeutic targeting. World Journal of Gastroenterology 2026; 32(27): 116347 doi: 10.3748/wjg.116347
|